Brief: Appili Therapeutics Announces U.S. FDA Approval Of Likmez Metronidazole Oral Suspension
25/09/2023 12:55
Sept 25 (Reuters) - Appili Therapeutics Inc APLI.TO :
* APPILI THERAPEUTICS ANNOUNCES U.S. FDA APPROVAL OF LIKMEZ™
(ATI-1501) METRONIDAZOLE ORAL SUSPENSION
* APPILI THERAPEUTICS INC - PATENT COVERAGE PROVIDES DRUG
MARKET
EXCLUSIVITY THROUGH AT LEAST 2039
* APPILI THERAPEUTICS - EXPECTS TO RECEIVE MILESTONE
PAYMENTS &
ROYALTIES FROM SAPTALIS BASED ON THIS FDA APPROVAL AND SAPTALIS'
COMMERCIALIZATION PLANS
Source text for Eikon: ID:nBw24bXMNa
Further company coverage: APLI.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez